Navigation

Cravit

Cravit - General Information

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]

 

Pharmacology of Cravit

Cravit, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Cravit is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.

 

Cravit for patients

While taking ofloxacin patient should be advised to:

  • to drink fluids liberally;
  • that mineral supplements, vitamins with iron or minerals, calcium-, aluminum-, or magnesium-based antacids, sucralfate or Videx, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;
  • that ofloxacin can be taken without regard to meals;
  • that ofloxacin may cause neurologic adverse effects (e. g., dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;
  • to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;
  • that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g., swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
  • to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g., skin eruption) occurs;
  • that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;
  • that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.
  •  

    Cravit Interactions

    Specific drug interaction studies have not been conducted with Levofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.

     

    Cravit Contraindications

    Levofloxacin solution is contraindicated in patients with a history of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this medication.

     

    Additional information about Cravit

    Cravit Indication: For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
    Mechanism Of Action: Cravit inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Cravit, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.
    Drug Interactions: Aluminium Formation of non-absorbable complexes
    Bismuth Formation of non-absorbable complexes
    Calcium Formation of non-absorbable complexes
    Iron Formation of non-absorbable complexes
    Magnesium oxide Formation of non-absorbable complexes
    Magnesium Formation of non-absorbable complexes
    Sucralfate Formation of non-absorbable complexes
    Zinc Formation of non-absorbable complexes
    Amiodarone Increased risk of cardiotoxicity and arrhythmias
    Bepridil Increased risk of cardiotoxicity and arrhythmias
    Bretylium Increased risk of cardiotoxicity and arrhythmias
    Chlorpromazine Increased risk of cardiotoxicity and arrhythmias
    Dihydroquinidine barbiturate Increased risk of cardiotoxicity and arrhythmias
    Disopyramide Increased risk of cardiotoxicity and arrhythmias
    Erythromycin Increased risk of cardiotoxicity and arrhythmias
    Fluphenazine Increased risk of cardiotoxicity and arrhythmias
    Josamycin Increased risk of cardiotoxicity and arrhythmias
    Mesoridazine Increased risk of cardiotoxicity and arrhythmias
    Methotrimeprazine Increased risk of cardiotoxicity and arrhythmias
    Perphenazine Increased risk of cardiotoxicity and arrhythmias
    Prochlorperazine Increased risk of cardiotoxicity and arrhythmias
    Quinidine Increased risk of cardiotoxicity and arrhythmias
    Propiomazine Increased risk of cardiotoxicity and arrhythmias
    Promazine Increased risk of cardiotoxicity and arrhythmias
    Promethazine Increased risk of cardiotoxicity and arrhythmias
    Procainamide The quinolone increases the effect of procainamide
    Quinidine barbiturate Increased risk of cardiotoxicity and arrhythmias
    Quinupristin This combination presents an increased risk of toxicity
    Sotalol Increased risk of cardiotoxicity and arrhythmias
    Thiethylperazine Increased risk of cardiotoxicity and arrhythmias
    Thioridazine Increased risk of cardiotoxicity and arrhythmias
    Trifluoperazine Increased risk of cardiotoxicity and arrhythmias
    Triflupromazine Increased risk of cardiotoxicity and arrhythmias
    Warfarin The quinolone increases the anticoagulant effect
    Acenocoumarol The quinolone increases the anticoagulant effect
    Dicumarol The quinolone increases the anticoagulant effect
    Anisindione The quinolone increases the anticoagulant effect
    Food Interactions: Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels.
    Generic Name: Levofloxacin
    Synonyms: L-Ofloxacin
    Drug Category: Anti-Bacterial Agents; Quinolones; Anti-Infective Agents, Urinary
    Drug Type: Small Molecule; Approved

    Other Brand Names containing Levofloxacin: Cravit; Cravit Ophthalmic; Elequine; Floxel; Iquix; Leroxacin; Lesacin; Levaquin; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Quixin; Reskuin; Tavanic; Volequin;
    Absorption: Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
    Toxicity (Overdose): Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
    Protein Binding: 24-38% (to plasma proteins)
    Biotransformation: Not Available
    Half Life: 6-8 hours
    Dosage Forms of Cravit: Solution Intravenous
    Tablet Oral
    Chemical IUPAC Name: (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate
    Chemical Formula: C18H20FN3O4
    Levofloxacin on Wikipedia: https://en.wikipedia.org/wiki/Levofloxacin
    Organisms Affected: Enteric bacteria and other eubacteria